From €117EUR$129USD£100GBP
- Report
- January 2025
- 132 Pages
Global
From €863EUR$950USD£733GBP
- Report
- October 2023
- 306 Pages
Global
From €2271EUR$2,499USD£1,929GBP
€3245EUR$3,570USD£2,755GBP
- Report
- October 2023
- 497 Pages
Global
From €2271EUR$2,499USD£1,929GBP
€3245EUR$3,570USD£2,755GBP
- Report
- August 2023
- 389 Pages
Global
From €2271EUR$2,499USD£1,929GBP
€3245EUR$3,570USD£2,755GBP
- Report
- August 2023
- 250 Pages
Global
From €2271EUR$2,499USD£1,929GBP
€3245EUR$3,570USD£2,755GBP
- Report
- June 2023
- 313 Pages
Global
From €2271EUR$2,499USD£1,929GBP
€3245EUR$3,570USD£2,755GBP
- Report
- October 2022
- 251 Pages
Global
From €2271EUR$2,499USD£1,929GBP
€3245EUR$3,570USD£2,755GBP
- Report
- February 2021
- 181 Pages
Europe
From €2362EUR$2,598USD£2,006GBP
€3374EUR$3,712USD£2,865GBP
- Book
- May 2024
- 208 Pages
- Book
- April 2023
- 176 Pages
- Book
- March 2023
- 576 Pages
- Book
- August 2022
- 448 Pages
- Book
- March 2022
- 368 Pages
- Book
- January 2022
- 448 Pages
- Book
- October 2019
- 720 Pages
- Book
- April 2019
- 288 Pages
- Book
- April 2018
- 200 Pages

The Antimicrobial Resistance (AMR) market is a subset of the healthcare services industry that focuses on the development of treatments and strategies to combat the growing threat of drug-resistant bacteria. AMR is a major public health concern, as it can lead to increased morbidity and mortality, as well as higher healthcare costs. To address this issue, the market is focused on developing new antibiotics, diagnostics, and vaccines, as well as strategies to reduce the spread of drug-resistant bacteria. Additionally, the market is focused on improving the stewardship of existing antibiotics, as well as developing new strategies to reduce the emergence of drug-resistant bacteria.
Some companies in the AMR market include Merck & Co., Pfizer, GlaxoSmithKline, Sanofi, Johnson & Johnson, Novartis, and AstraZeneca. Show Less Read more